ClinicalTrials.gg
RecruitingNCT06641206Updated Oct 15, 2024

Intra-Articular Dexmedetomidine: A Treatment for Chronic Knee Pain

An interventional study of Triamcinolone Acetonide and Bupivacaine Hydrochloride in Chronic Knee Pain, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Tanta University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies testing Triamcinolone Acetonide in Pain — 4 open to participants now, 4 under way, 2 of them phase 3. Triamcinolone Acetonide · Pain.

Planned enrollment
10th of 17
70 · median 81
Started
2024
the only one that year
No phase
2 of 17
2 open now
Registered
14th of 17
by date
Lead sponsor
1 of 17
Tanta University

Among the 17 studies testing Triamcinolone Acetonide in Pain, this one is the 10th largest by planned enrollment, is the only one that started in 2024, is one of 2 with no phase, and was the 14th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

4 of the 17 studies testing Triamcinolone Acetonide in Pain are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About Triamcinolone Acetonide

Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing Triamcinolone Acetonide in Pain, or all of them as a file.
02

Study summary

Chronic knee osteoarthritis (KOA) is a painful condition with limited treatment options. Non-pharmacological approaches often fall short, leading to decreased quality of life. Ozone therapy, a simple and affordable treatment, has shown promise for pain relief. Dexmedetomidine (DEX), a sedative and analgesic, has been used successfully as an adjuvant to anesthesia and local anesthetics. Given its potential for pain management, exploring DEX as a treatment for KOA could offer a new and promising approach.

03

Conditions studied

  • Chronic Knee Pain

Browse trials for

04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients were not assigned for surgical intervention;
  • Patients were free of exclusion criteria

Exclusion criteria

Exclusion Criteria:

  • Patients were assigned for surgical intervention;
  • Patients who had uncontrolled hypertension and/or diabetes mellitus;
  • Patients who had uncompensated cardiac, renal, or hepatic diseases;
  • Patients with coagulopathy, spinal deformity, allergy, or for the used drugs;
  • Patients who refused to sign the were excluded from the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
70 participants (estimated)

Study arms

  • Active comparator
    Group 1

    A group of Patients from Tanta University suffering from Chronic painful knee osteoarthritis who didn't receive medical treatment and progressed to have chronic pain with decreased physical function and poorer quality of life.

    Drug: Triamcinolone Acetonide · Drug: Bupivacaine Hydrochloride

  • Active comparator
    Group 2

    A group of Patients from Tanta University suffering from Chronic painful knee osteoarthritis who didn't receive medical treatment and progressed to have chronic pain with decreased physical function and poorer quality of life.

    Drug: Dexmedetomidine

Interventions

  • 1 ml of triamcinolone acetonide was used to prepare a solution for knee injection for patients with Chronic Knee Pain

  • DrugBupivacaineStudies of BupivacaineBupivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    20mg of bupivacaine hydrochloride was used to prepare a solution for knee injection for patients with Chronic Knee Pain

  • Dexmedetomidine solution was prepared by mixing Dexmedetomidine in a dose of 3 µg/kg in 5-ml saline

06

What researchers measure

Primary outcomes

  1. Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-intra-articular Injection.

    Value of intra-articular Injection in Pain Reduction of chronic knee pain manifested by recurrence of pain.

    Time frame: 7 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Jan 2025, 4 months after the start.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 4 months is below that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2024
First posted
Oct 15, 2024
StartActual
Sep 17, 2024
Primary completionEst.
Jan 2025
CompletionEst.
Mar 2025
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06641206
Lead sponsor
Tanta University
Responsible party
Ahmed ElKashef (lecturer of Anesthesia and Surgical ICU, Faculty of Medicine, Tanta University) — Principal investigator
First posted
Oct 15, 2024
Start date
Sep 17, 2024
Primary completion
Jan 2025 (estimated)
Completion
Mar 2025 (estimated)
Last update
Oct 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Triamcinolone Acetonide · Bupivacaine · Dexmedetomidine

Start the discussion